Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)

Glioblastoma Clinical Trial

— MIRROR  

Official title:

Multispectral and Bimodal Fluorescent Guided Surgery (FGS) of High-grade Glioma for Refining Margin Assessment: A Phase 1 Dose Finding Study Using Cetuximab-IRDye800CW Combined With 5-ALA.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05929456
• Other study ID #: NC2022-01
• Status: Recruiting
• Phase: Phase 1
• Start date: May 5, 2023
• Est. completion date: January 1, 2025

Study information

• Verified date: June 2023
• Source: University Medical Center Groningen
• Contact: Yester Janssen, MD
• Phone: +316 15 17 09 00
• Email: y.f.janssen[@]umcg.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The MIRROR study is a prospective, single center phase I feasibility and dose finding study in patients with high-grade glioma, to establish the safety, feasibility, and optimal dosage of Cetuximab-IRDye800CW for fluorescence guided surgery, in comparison to the standard of care (SOC), 5-ALA fluorescent imaging agent. The main research objectives of this study are: 1. To determine the optimal dosage of Cetuximab-IRDye800CW for fluorescence guided surgery 2. To assess the safety and tolerability 3. To correlate fluorescent signals measured by in vivo multispectral imaging with Cetuximab-IRDye800CW and 5-ALA with those measured by ex vivo imaging The study population will consist of patients, aged ≥18 years, diagnosed with high-grade glioma and scheduled for surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 21
• Est. completion date: January 1, 2025
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing to adhere to the prohibitions and restrictions specified in this protocol.
• Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study and is willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol.
• Patients aged = 18 years inclusive at moment signing informed consent form.
• Established high-grade glioma (glioblastoma, grade 4 according to the WHO (World Health Organization) classification) and scheduled for surgical intervention.
• Life expectancy of > 12 weeks.
• Karnofsky performance status of at least 70%.
• No clinically significant laboratory abnormalities as determined by the investigator o Note: one retest of lab tests is allowed within the screening window
• Female patients should fulfil one of the following criteria:
• At least 1 year post-menopausal (amenorrhea >12 months) at screening
• Surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation)
• Women >18 years of age who are fertile, need to agree to use an adequate form of contraceptives during and till 3 months after the study. Before study enrollment, a pregnancy test in blood or urine will be performed to rule out a pregnancy. In the case of an unlikely pregnancy during the study, they accept the possible maternal/ fetal risk of participation in the study. Exclusion Criteria:

General:

• Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the patient to understand and cooperate with the study protocol
• Deprived of freedom by an administrative or court order or in an emergency setting.
• Insufficient venous access for the study procedures.
• Close affiliation with the investigator; e.g. a close relative of the investigator, dependent person (e.g. employee or student), employee of the department of Neurosurgery of the UMCG (University Medical Center Groningen), or affiliates
• Any finding in the medical examinations or medical history giving, that in the opinion of the investigator, leads to a reasonable suspicion of a disease or condition that makes treatment with the investigational drug unadvisable, or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications
• Participation in an interventional clinical study within 30 days prior to tracer administration that involved treatment with any drug (excluding vitamins and minerals) or medical device Medical conditions
• Concomitant malignancies, including metastasized colon-, rectal-, breast carcinoma, non-small cellular lung carcinoma (NSCLC); primary epithelial ovarian-, fallopian tube-, primary peritoneal- or cervical carcinoma.
• Any abnormalities in the vital signs of the patient, as judged by the investigator, as a result of which the patient cannot participate
• eGFR (based on plasma-creatinine) outside of normal range at screening or known renal impairment (=40 mL/min).
• Current evidence or history of bacterial, viral or fungal infections within 7 days before Cetuximab-IRDye800CW administration, as judged by the Investigator. o T > = 38.0°C or lab confirmed viral/bacterial/fungal infection (PCR)) or symptoms suggestive of an infection)
• Any laboratory test which is abnormal, and which is deemed by the Investigator(s) to be clinically significant
• A history of anaphylaxis, history of allergic reaction(s), known allergy to one of the drugs or excipients administered as part of this study. Mild allergies without angioedema or treatment need can be acceptable if deemed not to be of clinical significance (including but not limited to allergy to animals or mild seasonal hay fever)

Related Conditions & MeSH terms

• Glioblastoma
• Glioma
• High-grade Glioma

Intervention

Drug:
• Cetuximab-IRDye800
patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.

Locations

Country	Name	City	State
Netherlands	UMCG	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Optimal dosage	To determine the optimal dosage of Cetuximab-IRDye800CW for fluorescence guided surgery of high-grade glioma using Near- Infrared (NIR) fluorescence imaging	1 day
Primary	To assess the safety and tolerability of intravenous tracer administration by measuring/registering the number(S)AEs and SUSARs that have occurred during the duration of the trial	The (S)AEs and SUSARS will be reported according to the CTCAE v4.0	4-5 days
Primary	In vivo/ex vivo correlation	To correlate fluorescent signals measured by in vivo multispectral imaging with Cetuximab-IRDye800CW and 5-ALA with those measured by ex vivo imaging	1 day
Secondary	Fluorescent signals vs pathology	To correlate the presence of pathologically confirmed EGFR(epidermal growth factor receptor)-gene amplification with the presence of fluorescence signals, in- and ex vivo, as measured with NIR fluorescent imaging after administering Cetuximab-IRDye800CW.	1 day
Secondary	DSC biomarkers	Correlation between DSC (dynamic susceptibility contrast) biomarkers with pathological EGFR-gene amplification status.	1 day